Navigation Links
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
Date:8/3/2009

h as simplified access to EMEA's scientific consulting resources. This initiative helps to give patients suffering from rare diseases access to the same quality of treatment as other patients.

(1) Topp, M.S. et al (2009). Blinatumomab (anti-CD19 BiTE(R)) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II study. 14th Congress of the EHA 2009, abstract no. 482

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is license
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Announces Pricing of Public Offering of Common Stock
2. Micromet Announces Public Offering of Common Stock
3. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
4. Micromet Added to Russell 3000 Index
5. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
6. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
7. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
8. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
9. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
10. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
11. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 30, 2014 The evening of ... decades-long heritage in successful medical device development to ... what it takes to successfully innovate in the ... of a two-hour on-site class, Insight gave master’s ... business, McCormick School of Engineering, medical and law ...
(Date:10/31/2014)... October 31, 2014 The report ... Rice), Formulation (Plain, Flavored, Sweetened, Unsweetened), Channel (Supermarket, ... Global Trends & Forecast to 2018," defines and ... analysis and forecast of revenue and volume for ... is projected to reach $14 Billion by 2018 ...
(Date:10/31/2014)... Oct. 31, 2014  Atlanta-based Intellimedix could make ... the onset of Ebola by suggesting a new, ... Georgia Tech,s Center for Computational Systems Biology have ... find alternative uses for existing drugs through systematic ... aid the bout against Ebola. ...
(Date:10/30/2014)... 30, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Naltrexone HCL information, including its definition, classification, application, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
Breaking Biology Technology:Insight Product Development Gives Northwestern University Students Foundation for Innovation Success 2Insight Product Development Gives Northwestern University Students Foundation for Innovation Success 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3
... National Business Group on Health Names Leading Companies that Promote a ... ... The National Business,Group on Health (NBGH), a national non-profit organization of ... and promoting a healthy lifestyle for employees and their,families., GSK ...
... with Improved Usability & ... ... high incidence,of women,s health conditions that require intra-vaginal drug delivery and,the ... an alarming majority of women find their current treatment,options "unacceptable" or ...
... Germany, May 13 Caviar has become one ... view of the over fished,sturgeon populations in the ... sustainable aquaculture. United Food Technologies AG (UFT) has ... know-how in this sector.,This week, the company delivered ...
Cached Biology Technology:GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles 2GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles 3GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles 472% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds 2Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant 2
(Date:10/29/2014)... air pollutants released by unconventional oil and gas production ... published today in the open access journal Environmental ... formaldehyde were found. The study is the first to ... near production sites and could be used to supplement ... come from reserves that do not readily flow to ...
(Date:10/29/2014)... largest study of its kind to date, researchers have ... heighten the risk for autism. Joseph Buxbaum, Ph.D., Icahn ... Mark Daly, Ph.D., Broad Institute of Harvard and MIT, ... from affected children, parents and unrelated people. They identified ... to the risk for autism spectrum disorder (ASD) – ...
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... the time, the immune system is the body,s protector, warding ... infection and disease. But in autoimmune diseases, the immune ... attacking normal cells. A major discovery by La Jolla ... previously unknown molecular interaction that is essential for T lymphocyte ...
... team of Russian veterinary colleagues and health experts from the ... distemper -- a virus afflicting domestic dogs and many wildlife ... tigers. The team presented its results at the first-ever ... Russian Far East city of Ussurisk. The symposium underscores ...
... stem cell therapies will be among the research topics ... on Cardiovascular Regenerative Medicine, which will be held Oct. ... into the state of the regenerative medicine field. ... Lung, and Blood Institute and the Foundation for the ...
Cached Biology News:La Jolla Institute discovers previously unknown cell interaction key in immune system attacks 2La Jolla Institute discovers previously unknown cell interaction key in immune system attacks 3Russian and US veterinarians collaborate to solve mysterious wild tiger deaths 2Russian and US veterinarians collaborate to solve mysterious wild tiger deaths 3NIH hosts Cardiovascular Regenerative Medicine Symposium Oct. 4-5 2
... GeneMaths XT is undoubtedly the most complete ... advanced concept of layers and subsets makes ... layers for different data outputs, for example ... etc., as well as different subsets of ...
...
...
... several important steps of angiogenesis including proliferation, migration, ... reduces intracellular reactive oxygen species (ROS) level, H(2)O(2)-dependent ... Formula: ... MolWeight: 360.31484 Store ...
Biology Products: